Shares of Aimmune Therapeutics Inc. (Nasdaq: AIMT) surged $7.28 to close at $32.94 after rival DBV Technologies (Nasdaq: DBVT) reported disappointing results from a Phase 3 study of the peanut allergy treatment AR101. DBV Technologies stock collapsed $19.75 to close at $28.32.
Aimmune Therapeutics soars on DBV Technologies' disappointing results
October 23, 2017 at 17:13 PM EDT
